Last reviewed · How we verify

177Lu-FAP-2286 — Competitive Intelligence Brief

177Lu-FAP-2286 (177Lu-FAP-2286) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Radiolabeled antibody. Area: Oncology.

phase 2 Radiolabeled antibody Folate receptor alpha (FRα) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

177Lu-FAP-2286 (177Lu-FAP-2286) — Peter MacCallum Cancer Centre, Australia. 177Lu-FAP-2286 is a radiolabeled antibody that targets folate receptor alpha (FRα) for the treatment of cancer.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
177Lu-FAP-2286 TARGET 177Lu-FAP-2286 Peter MacCallum Cancer Centre, Australia phase 2 Radiolabeled antibody Folate receptor alpha (FRα)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Radiolabeled antibody class)

  1. Peter MacCallum Cancer Centre, Australia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). 177Lu-FAP-2286 — Competitive Intelligence Brief. https://druglandscape.com/ci/177lu-fap-2286. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: